Cardiovascular events related to atherosclerosis are responsible for high morbidity and
mortality among patients with type 2 diabetes. Improvement in care, especially in early …

Abstract Introduction Type 2 diabetes (T2D) management has reached a point where not
only optimal glycaemic control is necessary, but also additional interventions with proven …

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …

Background: Cardiovascular morbidity and mortality are a major burden in patients with type
2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 …

In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been
released with significant effects on glucose lowering and weight reduction. One of the most …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …

ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, and in a
glucose-dependent manner stimulates insulin secretion while inhibiting glucagon secretion …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …

Objective: The purpose of this article is to review the pharmacological characteristics and
clinical evidence of oral semaglutide for the treatment of type 2 diabetes mellitus (T2DM) …